(0.37%) 5 110.25 points
(0.79%) 38 684 points
(0.64%) 17 762 points
(0.28%) $79.17
(-0.15%) $2.03
(-0.03%) $2 308.90
(-0.16%) $26.79
(1.16%) $973.80
(-0.13%) $0.931
(-0.64%) $10.92
(-0.18%) $0.796
(0.49%) $91.58
4 days till quarter result
(amc 2024-05-07)
Expected move: +/- 7.57%
@ $3.65
发出时间: 14 Feb 2024 @ 22:30
回报率: -19.77%
上一信号: Feb 13 - 04:55
上一信号:
回报率: -6.48 %
Live Chart Being Loaded With Signals
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases...
Stats | |
---|---|
今日成交量 | 1.11M |
平均成交量 | 1.73M |
市值 | 431.79M |
EPS | $0 ( 2024-05-01 ) |
下一个收益日期 | ( $-0.350 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.880 |
ATR14 | $0.00900 (0.31%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Neupert Peter M | Buy | 15 000 | Common Stock |
2024-03-12 | Neupert Peter M | Sell | 15 000 | Stock Option (right to buy) |
2024-03-04 | Pellini Michael J | Buy | 31 328 | Common Stock |
2024-03-04 | Pellini Michael J | Buy | 48 044 | Stock Option (right to buy) |
2024-03-04 | Owen Katey Einterz | Buy | 31 328 | Common Stock |
INSIDER POWER |
---|
61.57 |
Last 100 transactions |
Buy: 4 473 782 | Sell: 1 037 795 |
音量 相关性
Adaptive Biotechnologies 相关性 - 货币/商品
Adaptive Biotechnologies 财务报表
Annual | 2023 |
营收: | $170.28M |
毛利润: | $72.49M (42.57 %) |
EPS: | $-1.560 |
FY | 2023 |
营收: | $170.28M |
毛利润: | $72.49M (42.57 %) |
EPS: | $-1.560 |
FY | 2022 |
营收: | $185.31M |
毛利润: | $127.40M (68.75 %) |
EPS: | $-1.000 |
FY | 2021 |
营收: | $154.34M |
毛利润: | $105.04M (68.06 %) |
EPS: | $-1.580 |
Financial Reports:
No articles found.
Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。